The generation and function of soluble apoE receptors in the CNS

G William Rebeck  
*Georgetown University*

Mary Jo LaDu  
*University of Illinois at Chicago*

Steven Estus  
*University of Kentucky*

Guojun Bu  
*Washington University School of Medicine in St. Louis*

Edwin J. Weeber  
*Vanderbilt University*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

*Part of the Medicine and Health Sciences Commons*

Please let us know how this document benefits you.

**Recommended Citation**

Rebeck, G William; LaDu, Mary Jo; Estus, Steven; Bu, Guojun; and Weeber, Edwin J., "The generation and function of soluble apoE receptors in the CNS." Molecular Neurodegeneration. 1, 15. (2006).

[https://digitalcommons.wustl.edu/open_access_pubs/185](https://digitalcommons.wustl.edu/open_access_pubs/185)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
The generation and function of soluble apoE receptors in the CNS
G William Rebeck¹, Mary Jo LaDu², Steven Estus³,⁴, Guojun Bu⁵,⁶,⁷, and Edwin J Weeber*⁸,⁹,¹⁰

Address: ¹Department of Neuroscience, Georgetown University, Washington DC, USA, ²Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, USA, ³Department of Physiology, University of Kentucky, Lexington, USA, ⁴Sanders-Brown Center on Aging, University of Kentucky, Lexington, USA, ⁵Department of Pediatrics, Washington University, St. Louis, USA, ⁶Department of Cell Biology and Physiology, Washington University, St. Louis, USA, ⁷Hope Center for Neurological Disorders, Washington University, St. Louis, USA, ⁸Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, USA, ⁹Department of Pharmacology, Vanderbilt University, Nashville, USA and ¹⁰Vanderbilt Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, USA

Email: G William Rebeck - gwr2@georgetown.edu; Mary Jo LaDu - maryjo03@comcast.net; Steven Estus - sestus2@email.uky.edu; Guojun Bu - bu@kids.wustl.edu; Edwin J Weeber* - edwin.j.weeber@vanderbilt.edu

* Corresponding author

Abstract
More than a decade has passed since apolipoprotein E4 (APOE-ε4) was identified as a primary risk factor for Alzheimer’s disease (AD), yet researchers are even now struggling to understand how the apolipoprotein system integrates into the puzzle of AD etiology. The specific pathological actions of apoE4, methods of modulating apolipoprotein E4-associated risk, and possible roles of apoE in normal synaptic function are still being debated. These critical questions will never be fully answered without a complete understanding of the life cycle of the apolipoprotein receptors that mediate the uptake, signaling, and degradation of apoE. The present review will focus on apoE receptors as modulators of apoE actions and, in particular, explore the functions of soluble apoE receptors, a field almost entirely overlooked until now.

Background
ApoE and apoE receptors
Apolipoprotein E (apoE) is a small (34-kDa) secreted glycoprotein that associates with lipoproteins and mediates uptake of these particles into target cells via receptor-mediated endocytosis by the low density lipoprotein (LDL) receptor family. Three commonly occurring isoforms have been identified in the human population due to single nucleotide polymorphisms on the APOE gene on chromosome 19. The apoE3 isoform (Cys112, Arg158) occurs at the highest frequency, followed by apoE4 (Arg112, Arg158) and apoE2 (Cys112, Cys158). ApoE is a ligand for the seven identified mammalian members of the evolutionarily conserved low density lipoprotein (LDL) receptor family: the low density lipoprotein receptor (LDLR), apoE receptor 2 (ApoER2), the very low density lipoprotein receptor (VLDLR), multiple epidermal growth factor (EGF) repeat-containing protein (MEGF7), megalin, LDL-related protein-1 (LRP1) and LDL-related protein-1b (LRP1b). APOE was initially recognized for its importance in lipoprotein metabolism and cardiovascular disease, however, more recently it has been studied for its role in several biological processes not directly related to lipoprotein transport. The following review will focus on the role of apoE and apoE receptors in the CNS with a focus on the processing and production of soluble apoE receptors.
Alzheimer’s disease (AD) is a complex neurodegenerative condition characterized neuropathologically by the presence of extracellular amyloid plaques, intraneuronal neurofibrillary tangles, and neuronal loss. While most AD is sporadic in nature, two classes of genetic risk factors for AD have been identified. The first class consists of mutations responsible for the rare, familial AD (FAD). Genes implicated in FAD include the β-amyloid protein precursor (APP), presenilin-1, and presenilin-2; mutations in these genes produce AD risk marked by autosomal dominance, early disease onset, high penetrance, and relative rarity, on the order of hundreds of families worldwide (reviewed in [1]). Each of the mutated forms of these genes enhances the production of amyloid-β (Aβ) peptide [2], particularly the 42 amino acid form (Aβ42). Because Aβ42 aggregates to form amyloid, the discovery of these genes strongly supports the “amyloid hypothesis” [2].

A second class of AD risk factor is genetic variation that modulates the sporadic late onset AD; at present, the sole member of this class is the APOE gene. APOE encodes a secreted protein of 299 amino acids important for the transport of cholesterol. Single nucleotide polymorphisms (SNP) define three common alleles (ε2, ε3, and ε4), which encode proteins that differ at two amino acids. APOE-ε2 is associated with reduced odds and delayed onset of AD while APOE-ε4 is associated with increased odds and earlier onset of AD [3]. APOE-ε4 appears to account for up to 40–50% of the genetic risk of AD [4,5]. Furthermore, APOE-ε4 is associated with increased brain Aβ burden are seen in mice as well, with studies in mice demonstrating the role for apoE in Aβ fibrillogenesis and neurtic plaque formation [7,8]. Importantly, the risk associated with APOE-ε4 is modulated by other unknown genetic and environmental factors.

AD has a complex etiology that encompasses environmental factors as well as the genetic risk factors. The existence of environmental risk factors is demonstrated by multiple lines of evidence, including studies of twins. Interestingly, it was found that only about half of identical twins have concordance for AD [9,10]. Among the environmental factors identified, cholesterol lowering treatments (reviewed in [11,12]) and anti-inflammatory drugs (reviewed in [13]) may decrease risk of AD. Alternatively, analysis of post-mortem AD brains showed an increased level of traumatic brain injury compared to normal non-AD brains, suggesting that brain trauma may significantly increase the risk of AD [14]. ApoE is potentially involved in each of these environmental factors.
protein (RAP) [69]. RAP is an endoplasmic reticulum (ER)-resident protein that functions in receptor folding and trafficking along the early secretory pathway and universally antagonizes ligand-binding to all members of the family [69].

Many of the apoE receptors have been found in the CNS. Neurons express LDLR, LRP, ApoER2, and the VLDLR; astrocytes express LDLR and LRP; microglia express VLDLR and LRP [6,57,70-73]. It is unclear which receptors are expressed on oligodendrocytes. Soluble forms of each of these receptors have been detected (see below).

ApoE receptors and endocytosis

A major function of at least some of the apoE receptors is clathrin-mediated endocytosis. The rapid endocytosis rate of LRP is unique among LDLR family members. The dominant endocytosis signal for LRP is the YXXL motif [74]. The two copies of the NPXY motif, which mediates LDLR endocytosis [75], do not play significant roles in LRP endocytosis but likely bridge interactions with adaptor proteins for signaling and intracellular trafficking. The initial endocytosis rates of individual LDLR family members are significantly different with half time for internalization ranging from <0.5 min (LRP) to >8 min (ApoER2/VLDLR) ([76], see Table 1). These results suggest endocytic functions among LDLR family members are distinct.

In addition to endocytosis, LDLR family members also exhibit efficient recycling. In particular, sorting nexin 17, a member of the PX-domain containing, sorting nexin family, interacts with the proximal NPXY motif of the LRP tail and promotes its recycling in the early endosome [77]. Other adaptor proteins, specifically Dab-1 and FE65, affect levels of surface apoE receptors [78]. Although significant cholesterol from the periphery does not get transported into the CNS and sufficient cholesterol is synthesized in the CNS [79], cholesterol redistribution is important for transport of cholesterol from glia to neurons [80] and for clearance of membrane debris after CNS damages [81].

ApoE receptors and intracellular signaling

Recently, several studies have demonstrated a role for some apoE receptors (specifically LRP, ApoER2, and VLDLR) as signaling molecules (see [53,82] for review). VLDLR and ApoER2 transduce signals from the extracellular matrix molecule Reelin, affecting neuronal cell migration during development [83]. LRP activation by ligand binding affects NMDA receptor function [84-89]. These effects are transduced through the cytoplasmic domains of receptors binding various cytoplasmic adaptor and scaffold proteins containing PID or PDZ domains, including mammalian Disabled-1 (mDab1), mDab2, FE65, JNK-interacting protein JIP-1 and JIP-2, and PSD-95 [90-95]. ApoE receptor ligands also promote other intraneuronal signals via apoE receptors, including PI3 activation, ERK activation, and JNK inhibition [86,96,97] but exactly which receptors promote which signals is unknown. ApoE receptors on glia also affect signaling pathways, affecting the state of glial activation [41,42,98].

ApoE receptors and synaptic plasticity

These receptor-mediated processes defined in vitro are important for brain physiological functions. The apoE receptor antagonist RAP prevents induction of long-term potentiation (LTP) in hippocampal slices [69]. ApoER2 and VLDLR knock-out (KO) mice have normal baseline synaptic transmission, as measured in acute hippocampal slices, but have subtle impairment of hippocampal LTP [83,99]. Moreover, Reelin application enhanced LTP induction, which was dependent on the presence of both ApoER2 and VLDLR [97]. A potential molecular mechanism for this function of ApoER2 is a 59 amino acid cytoplasmic domain that is alternatively spliced. This ApoER2 splice variant interacts with PSD-95, which is itself associated with NMDA receptor conductance [87,95]. Knock-in mice exclusively expressing ApoER2 receptors that lack the 59 amino acid insert exhibit decreased LTP induction, and no enhancement of LTP in the presence of exogenous Reelin [87]. Thus, the role of ApoER2 in LTP appears to be in the capacity of NMDA receptor modulation by increasing...
ApoE isoforms and synaptic plasticity

Increasing evidence indicates that apoE4 itself impairs neuronal viability. Not all cell types are susceptible to apoE4-induced toxicity; glia are relatively resistant [100] and only cells with a neuronal phenotype appear vulnerable [101]. ApoE4 actually inhibits neurite outgrowth, overrides the neurite-stimulatory effect of apoE3 and is neurotoxic in vitro (reviewed by Teter [102]). Transgenic expression of human apoE4 has dominant negative behavioral effects [103-106], including deficits in memory tasks [103,105]. In addition, apoE4 mice exhibit a greater memory impairment than apoE-knockout (apoE-KO) mice, suggesting that apoE4 confers a gain of negative function [106,107].

Several studies utilizing genetically altered mice have begun to shed light on the roles of apoE in synaptic plasticity and memory formation. ApoE targeted replacement mice (apoE-TR mice) express one of the three human isoforms under the control of endogenous murine APOE promoter sequences in a conformation and at physiological levels in a temporal and spatial pattern comparable to endogenous mouse apoE [108]. ApoE-TR mice expressing the apoE3 isoform are identical to wild type mice in both LTP induction and spatial learning. In contrast, mice expressing the apoE4 isoform demonstrate compromised LTP induction and spatial learning. Importantly, the impaired spatial learning exhibited by apoE-deficient mice can be rescued by infusion of human apoE3 or apoE4 [109,110]. Thus, apoE and its receptors influence NMDA receptor activity, LTP, and spatial memory.

ApoE, Aβ, and synaptic plasticity

In addressing the effect of apoE on Aβ-induced changes in neuronal viability, it is unclear precisely what form of the Aβ peptide was used in early studies because it has been difficult to isolate and determine the conformational species of Aβ responsible for its neural activity [50,51]. In vitro, several recent studies have demonstrated that apoE2 and E3, but not E4, protect neurons against cell death induced by non-fibrillar Aβ, but have no effect on fibrillar-induced toxicity [111,112]. In addition, oligomeric Aβ42-induced neurotoxicity is significantly greater in both Neuro-2A cells treated with apoE4 [112-114] and primary co-cultures of wild-type (WT) neurons and glia from apoE-TR mice expressing apoE4 [47,112]. Using apoE-TR mice, oligomeric Aβ42-induced inhibition of LTP was greatest in hippocampal slice cultures from apoE4-TR mice, while apoE2 actually protected against LTP impairment [46]. In vivo, crossing apoE2 transgenic mice with APP transgenic mice prevented soluble Aβ-induced dendritic spine loss [115].

Summary

Of the two major apolipoproteins found in the CSF, apoE can associate to a number of extracellular molecules and bind to four major CNS apoE receptors; VLDLR, ApoER2, LDLR and LRP. The apoE4 isoform has garnered attention due to the genetic association of apoE4 inheritance and AD risk. ApoE receptors undergo rapid clathrin-mediated endocytosis following ligand binding and have the ability to link ligand binding to several signal transduction pathways. ApoE isoforms exhibit a differential affect on synaptic function and VLDLR and ApoER2 are shown to play a role in synaptic plasticity and memory formation.

ApoE receptors and AD

ApoE receptors are an integral part of normal apoE metabolism, potentially mediating and/or modulating the effects of apoE isoforms on AD pathological processes. They are also important for the cellular homeostasis of cholesterol, which may also affect Aβ production from APP [12]. Several lines of research have implicated apoE receptors directly in AD pathophysiology through several mechanisms (Figure 2).

ApoE receptors endocytose Aβ

Almost from the initial observations that apoE bound Aβ [24,34], apoE receptors have been suggested to act as clearance mechanisms for Aβ. Since then, apoE receptors have been found to help transport Aβ across the endothelial cells forming the blood brain barrier [116] or clear Aβ into astrocytes as a degradative process [45]. ApoE is found on most, but not all Aβ deposits in the AD brain [117,118]. LRP is expressed on activated astrocytes [6] and closely associated with Aβ deposits [119]. The importance of Aβ clearance via apoE receptors is also supported by the significant increase in amyloid deposition observed in transgenic APP mice deficient in the RAP gene [120].

Table 1: ApoE receptor endocytosis rates.

| Receptor | t1/2  |
|----------|-------|
| LRP      | 0.5 min |
| LDLR     | 4.8 min |
| ApoER2   | 8.1 min |
| VLDLR    | 8.2 min |

NMDAR conductance and thus indirectly altering intracellular calcium levels.
which has increased levels of several LDLR family members [121,122]. Thus, the interactions of apoE complexes with the apoE receptors in the CNS vitally affect not only the metabolism of apoE, but of Aβ as well.

**LRP alters APP trafficking and processing**

ApoE receptors also have been implicated in the production of Aβ. LRP interacts with APP through the intracellular adaptor protein FE65 or via direct binding to the KPI domain [90,123-126]. Functionally, LRP’s rapid endocytosis facilitates APP endocytic trafficking and Aβ production [127-129]. Overexpression of a functional LRP minireceptor *in vivo* resulted in an increase of soluble Aβ in the brain [130].

**Other members of the LDLR family alter APP trafficking and processing**

The apoE receptor LRP1B, which undergoes a slow endocytosis, interacts with APP. However, unlike LRP, expression of LRP1B decreases APP endocytic trafficking and processing to Aβ [131]. ApoER2 also interacts with APP, through an extracellular matrix molecule F-spondin [132] and the intracellular adaptor protein FE65 [78]. These studies suggest that conditions that stabilize APP on the cell surface can increase α-cleavage of APP and decrease Aβ production. Finally, several recent studies have shown that SorLA/LR11 alters APP trafficking to discrete compartments such that APP processing by β/γ-secretases is decreased [133-136]. Together these studies indicate that

---

**Figure 2**

ApoE receptors and AD pathophysiology. ApoER2 and LRP receptors can mediate several intracellular signaling kinases including PI3K, CDK-5, JnK and MAPK. The splice variant of ApoER2 expressing exon 19 can influence calcium influx in response to ligand binding by modulating NMDA receptor-mediated currents via a Src-dependent mechanism. Signaling can also be influenced by apoE receptor – APP interaction and specific apoE isoform or Reelin binding.
binding to APP is a common event for the LDLR family members and expression and proteolytic processing of these receptors can impact APP trafficking and processing.

**Summary**

ApoE receptors are believed to act as a clearance mechanisms for extracellular Aβ and apoE is often associated with Aβ deposits in post mortem AD brains. The apoE receptors ApoER2, LRP and LRP1B can directly interact with and stabilize amyloid precursor causing increased α-cleavage and reduced Aβ producing cleavage. Thus, apoE and apoE receptors can influence both levels and production of Aβ.

**Soluble apoE receptors**

In addition to the transmembrane forms of apoE receptors, soluble forms of these receptors have been observed in vitro and in vivo (Figure 3). Soluble receptors can be generated by cleavage of transmembrane forms of the receptors (also called "ectodomain shedding"). Extracellular proteinases responsible for the release of soluble receptors are commonly metalloproteinases, either membrane bound (A Disintegrin and Metalloproteinase, ADAMs) or secreted (Matrix Metalloproteinase, MMPs) [137]. Alternatively, soluble receptors can be expressed from alternately spliced mRNAs that lack a transmembrane domain [138]. The LRP extracellular region undergoes shedding from a region close to the membrane by metalloproteinases to release soluble receptors as sLRP [139]. The LRP extracellular region undergoes shedding by metalloproteinases to release soluble receptors as sLRP [139].

Both of these processes are important for regulation of soluble apoE receptors and functions of membrane bound apoE receptors.

**Soluble LRP**

LRP is synthesized as a single polypeptide chain of ~600 kDa and then cleaved in the trans-Golgi network by furin into a 515-kDa ligand-binding subunit and an 85-kDa transmembrane subunit that remain non-covalently associated with one another as they traffic to the cell surface [139]. The LRP extracellular region undergoes shedding from a region close to the membrane by metalloproteinases, releasing a soluble LRP (sLRP) capable of binding ligands [140,141]. sLRP is detected in human plasma at nanomolar concentrations [140,141] and in human CSF [142]. Recent studies have also shown that the cell associated fragment of LRP can be cleaved at a third, intramembranous site by the γ-secretase, releasing its intracellular domain (ICD) [143,144]. These sequential cleavage events by furin, metalloproteinases, and γ-secretase closely resemble those of Notch family proteins [145-147].

**Soluble ApoER2 and VLDLR**

Like LRP, ApoER2 and VLDLR undergo extracellular cleavages by metalloproteinases to release soluble receptors as well as C-terminal, cell-associated fragments, and these events are induced by Phorbol esters [148]. Furthermore, the C-terminal fragments are cleaved by γ-secretase [149]. ApoER2 and VLDLR proteolytic events are also increased by extracellular ligand binding [148]. Interestingly, the different apoE alleles induced different degrees of release; both ApoER2 and VLDLR show greatest cleavage following apoE2 activation, less with apoE3 and relatively little with apoE4 [148]. The release of soluble forms of ApoER2 and VLDLR is affected by the presence of splice variants. ApoER2 and VLDLR both have prominent splice variants that lack the exon encoding an O-linked glycosylation site. This region is important in the regulated cleavage of transmembrane proteins [150]. In addition, some ApoER2 splice variants contain an exon that encodes a furin cleavage site in the extracellular domain [59,151]. Furin-dependent cleavage results in extrusion of a soluble fragment of the receptor [152]. Thus, cleavages of ApoER2 and VLDLR are regulated in part by alternate splicing events.

**Soluble LDLR**

Like the other family members, LDLR exists as a soluble form [153,154]. LDLR shedding from the cell surface is enhanced by several stimuli, including interferon and phorbol ester. As for the other apoE receptors, this effect is dependent upon a cell surface metalloproteinase [154]. Inefficient LDLR exon splicing may also contribute to soluble LDLR isoforms because LDLR ESTs have been reported which lack (i) exon 12, which causes a frameshift in the extracellular domain, resulting in a premature termination codon in exon 13, or (ii) exon 15, which encodes the LDLR O-linked glycosylation domain (BG945931 and BQ685399, respectively).

**Release of soluble receptors**

Numerous transmembrane proteins in addition to the apoE receptors have soluble forms, including growth factors and their receptors, cytokine precursors and receptors, cell adhesion molecules, enzymes, and differentiation factors [155]. To gain insight into the possible mechanisms of soluble apoE receptors, we will briefly consider the functions of released extracellular domains of various other transmembrane proteins.

1. **Protein function at a distance from the cell**

Certain transmembrane proteins have functions that are inactive as long as the protein is tethered to the cell surface. Upon cleavage, these proteins become active and their activities can be carried out at a distance from the cell. For example, TNF-α is synthesized as a membrane-bound, inactive protein but is activated by cleavage by the metalloproteinase TNF-α converting enzyme (TACE) [156]. Soluble TNF-α can then act as a cytokine in the maintenance of inflammation. Similarly, transforming growth factor-α (TGF-α) has a biologically active form on the cell surface, but its activity is limited to the cell surface. However, upon surface cleavage, an active TGF-α is
secreted and acts at a distance [157]. Another example of membrane bound protein cleavage is APP. Isoforms of APP containing the Kunitz proteinase inhibitor (KPI) domain can act as serine proteinase inhibitors at the cell surface but, once released from the cell surface, act as soluble proteinase inhibitors [158].

2. An initial step in cell signaling
Ligand binding to a cell surface receptor can transduce a signal inside the cell through several general mechanisms. One of these involves sequential cleavage of the surface receptor after ligand binding, releasing extracellular (soluble) and intracellular (membrane-bound) domains. A subsequent intramembranous (i.e. γ-secretase) cleavage of the membrane-associated protein then releases the cytoplasmic domain for intracellular effects [159]. Thus, release of the soluble receptor is a required step in the signal transduction pathway. The large number of proteins identified as γ-secretase substrates undergo this series of proteolytic events [160]. One well-studied example of this mechanism is the Notch receptor [161]. Notch is a receptor for cell surface proteins on adjacent cells (Delta, Jagged, etc.). After ligand binding, Notch undergoes sequential cleavages to release of its intracellular domain.

**Figure 3**
**Soluble apoE receptors.** Processing by γ-secretase cleaves ApoER2, VLDLR, and LRP1 at the membrane. Cleavage by furin can release soluble forms of ApoER2 and LRP. In addition, sheddase cleavage can result in soluble forms of all four receptors. Soluble ApoER2 fragments from furin or sheddase cleavage contain the ligand-binding regions necessary for interaction with Reelin and apoE. These soluble fragments can block endogenous ligand binding to full length receptor acting in a dominant negative fashion.
Cleavage at the cell surface would release soluble proteins. This requires a combination of proteolytic events. Transmembrane bound proteins, therefore, turnover of transmembrane proteins cannot be sufficiently degraded by either of these mechanisms as long as they are membrane bound. Therefore, turnover of transmembrane proteins requires a combination of proteolytic events. Cleavage at the cell surface would release soluble proteins for extracellular degradation or clearance. Subsequent cleavages within the membrane would generate small protein fragments that could be removed from the membrane, as well as cytoplasmic fragments that could be degraded by intracellular pathways. The urokinase receptor uPAR undergoes a series of cleavages that may be responsible for this type of protein turnover [174]. CD44 is another example of a protein that undergoes these sequential cleavages for degradation [175].

3. Inhibition of cell signaling
The soluble form of receptors can bind to soluble ligands and prevent them from interacting with membrane-bound receptors, thus preventing their effects on cells. High affinity receptors for several interleukins (IL-1, IL-4, IL-15) have shed forms that bind the specific interleukins and block their actions on cells [163-165]. A soluble version of the receptor for advanced glycation end products (RAGE) can block the interactions of ligands with the membrane bound forms of RAGE, preventing their endocytosis [166], and a soluble version of the leptin receptor blocks leptin signaling [167]. Receptor cleavage can also inhibit signaling that is already occurring on the cell surface. For example, cell surface ephrins interact with Eph receptors on adjacent cells, promoting both forward and reverse cell signaling cascades important in development [168]. The formation of the ligand receptor complex promotes cleavage of the ephrin from the cell surface by ADAMs, thus ceasing both forward and reverse signaling events [169].

4. Release of cell adhesion
Transmembrane proteins are vital for establishing stable connections of a cell with adjacent cells or with the extracellular matrix. When proteolysis of these membrane proteins occurs, the cellular binding to the extracellular matrix is broken, allowing a cell to migrate, or allowing portions of a cell to form new interactions. A component of the cleavage of the ephrin-Eph receptor complex is that this cleavage allows for the induced axonal repulsion [170]. Other examples include the cleavage of cell adhesion molecules L1 that disrupts cell-cell adhesion [171], and cleavage of the discoidan domain receptor 1, that disrupts cell-collagen adhesion [172].

5. Protein turnover
Secreted proteins are often degraded by soluble proteinases, or internalized by cells and degraded in endosomes and lysosomes. Cytoplasmic proteins can be ubiquitinated and degraded by the proteosome [173]. However, transmembrane proteins cannot be sufficiently degraded by either of these mechanisms as long as they are membrane bound. Therefore, turnover of transmembrane proteins requires a combination of proteolytic events. Cleavage at the cell surface would release soluble proteins for extracellular degradation or clearance. Subsequent cleavages within the membrane would generate small protein fragments that could be removed from the membrane, as well as cytoplasmic fragments that could be degraded by intracellular pathways. The urokinase receptor uPAR undergoes a series of cleavages that may be responsible for this type of protein turnover [174]. CD44 is another example of a protein that undergoes these sequential cleavages for degradation [175].

Functions of soluble apoE receptors
These potential functions of soluble receptors each apply to apoE receptors. One of the most profound implications of the production of soluble apoE receptors is the possible dominant negative effect on apoE receptor function. This action is observed with the production of soluble ApoER2. The expression of the ApoER2 variant containing the furin consensus site results in the production of soluble receptor consisting of the ligand binding domain [152]. Soluble ApoER2 can effectively block Reelin binding to both ApoER2 and VLDLR and subsequent Reelin-dependent signaling in primary neuronal cells. Thus, inhibition of normal Reelin signaling through ApoER2 and VLDLR can acutely modulate other signaling mechanisms through changes in NMDA receptor activity and intracellular signaling pathways [84-89]. The effect on apoE-dependent signaling has yet to be determined, but these studies suggest that selected apoE receptor shedding would affect both specific ligand binding, as in the case of soluble ApoER2 and Reelin signaling, as well as overall apoE binding and signaling.

Other soluble apoE receptors are shown to act in the same capacity as soluble ApoER2. Soluble LRP can bind RAP in ligand blots [140] and soluble derivatives of LRP, LDLR, and VLDLR have each been shown to mediate receptor-ligand interactions [140,152,176,177]. A physiologic function has yet to be ascribed to the production of soluble apoE receptors. However, in light of the essential roles these receptors play in synaptic function, integration into numerous signal transduction pathways and their wide-ranging of their ligands, it is likely that this type of negative feedback would be necessary in modulating the activity of specific or multiple apoE receptor subtypes. In addition, cleavage of apoE receptors could be a necessary step in receptor turnover, affecting receptor half-lives, and in preventing uptake of apoE-containing lipoproteins. In summary, release of soluble apoE receptors from the cell surface may modulate the cell surface apoE receptor pathway through multiple mechanisms, including ligand binding away from the cell, altered cell signaling, and differences in receptor degradation.
Summary

Numerous transmembrane receptors undergo proteolytic processing. Soluble apoE receptors have also been identified for VLDLR, ApoER2, LDLR and LRP. The specific physiologic function for apoE receptor processing has yet to be elucidated. However, a dominant negative effect has been attributed to the processing of ApoER2 and subsequent production of soluble receptor. Thus, specific apoE receptor shedding may represent a novel mechanism for modulating individual apoE receptor-ligand interactions and overall apoE receptor function.

Conclusion

Soluble apoE receptors are generated by two mechanisms, i.e., proteolysis of transmembrane receptors and by expression of alternately spliced isoforms of the proteins. Moreover, splicing also modulates cell surface proteolysis because exons encoding the O-linked glycosylation domains of VLDLR, ApoER2 and LDLR are alternatively spliced, and this glycosylation domain modulates susceptibility to cell surface proteolysis. These soluble receptors bind their ligands, including apoE, and affect their function and metabolism. The mechanisms and regulation of the processes generating soluble apoE receptors, mediating the actions of these receptors, and controlling the eventual clearance of the soluble receptors are just now being examined. Thus, soluble apoE receptors overall may represent an area of rapid growth in our understanding of AD-related processes. The importance of receptor shedding as a general regulatory mechanism is being recognized in many fields, with shedding of molecules important, for example, in development (Notch, Ephrins), immunology (TNF-α, IL-1 receptor, CD44), cell signaling (SREBP, leptin receptors), and cell adhesion (L1, discloidal domain receptor 1). Soluble apoE receptors could play roles as dominant negative regulators of apoE, and thus understanding their generation and actions are important for understanding normal apoE functions in the CNS.

References

1. Tanzi RE, Bertram L: Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 2005, 120(4):545-555.
2. Selkoe DJ: Alzheimer’s disease: genotypes, phenotypes, and treatments. Science 1997, 275(5300):630-631.
3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261(5123):921-923.
4. Lahiri DK, Sambamurti K, Bennett DA: Apolipoprotein E and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer’s disease. Neurobiol Aging 2004, 25(5):651-660.
5. Rocchi A, Pellegrini S, Siciliano G, Muri L: Causative and susceptibility genes for Alzheimer’s disease: a review. Brain Res Bull 2003, 61(1):1-24.
6. Rebeck GW, Reiter JS, Strickland DK, Hyman BT: Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron 1993, 11(4):573-580.
7. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius Lj, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM: Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 2000, 97(6):2892-2897.
8. Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM: Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer’s disease. J Clin Invest 1999, 103(6):R15-R21.
9. Breitner JC, Murphy EA: Twin studies of Alzheimer disease: II. Some predictions under a genetic model. Am J Med Genet 1992, 44(5):628-634.
10. Kenny GM, Engdal K, Kringlen E: The role of heredity in late-onset Alzheimer disease and vascular dementia. A twin study. Arch Gen Psychiatry 1997, 54(3):264-270.
11. Miller LJ, Chacko R: The role of cholesterol and statins in Alzheimer’s disease. Ann Pharmacother 2004, 38(1):91-98.
12. Wozniak D: Cholesterol, statins and dementia.Curr Opin Lipidol 2004, 15(6):667-672.
13. McGeer PL, Schulzer M, McGeer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology 1996, 46(5):252-342.
14. Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, Green RC, Sadowsnick AD, Duara R, DeCarli C, Johnson K, Go RC, Gwadon JH, Haines JL, Kukull WA, Farrer LA: Head injury and the risk of AD in the MIRAGE study. Neurology 2000, 54(6):1316-1323.
15. Pitas RE, Boylez JK, Lee D, Hui D, Weisgraber KH: Lipoprotein receptors and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B (LDL) receptors in the brain. J Biol Chem 1987, 262(29):14352-14360.
16. Koch S, Donarski N, Goesta K, Krekel M, Staurenberg HJ, Buhmann C, Beisiegel U: Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 2001, 42(7):1143-1151.
17. Rebeck GW, Alonzo NC, Berezovskaya O, Harr SD, Knowles RB, Gwadon JH, Hyman BT, Mendez AJ: Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes. Exp Neurol 1998, 149(1):175-182.
18. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD: Increased amyloid beta protein deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993, 90(20):9649-9653.
19. Greenberg SM, Briggs ME, Hyman BT, Gotakis Gj, Takis C, Kanter DS, Kase CS, Pessin MS: Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996, 27(8):1333-1337.
20. Rebeck GW, West HL, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, Stanley HE: Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci U S A 1995, 92(8):3586-3590.
21. Nicoll JA, Roberts GW, Graham DI: Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med 1995, 1(2):135-137.
22. Nicoll JA, Burnett C, Love S, Graham DI, Ironside JW, Vinters HV: High frequency of apolipoprotein E epsilon 2 in patients with cerebral hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1996, 39(5):682-683.
23. Lai F, Kammann E, Rebeck GW, Anderson A, Chen D, Nixon RA: APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology 1999, 53(2):331-336.
24. Namba Y, Tomonaga M, Kawasaki H, Otsuno E, Ikeda K: Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991, 541(1):163-166.
25. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid beta peptide deposition. Nat Genet 1997, 17(3):263-264.
26. Fryer JD, Taylor JW, Demattos RB, Bales KR, Page number not for citation purposes
dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurol Sci 2005, 231(1-2):709-788.

47. Ciselli AM, Bulthuis LC, Savelkoul PHM, LaDu MJ: Abeta42 neurotoxicity in primary co-cultures: Effect of apoE isoform and Abeta conformation. Neurobiol Aging 2006.

48. Whitson JS, Minns MP, Sritittipat W, Yamaki T, Morrisett JD, Appel SH: Attenuation of the neurotoxicity of A beta amyloid peptide by apolipoprotein E. Biochem Biophys Res Commun 1994, 199(1):163-170.

49. Ma J, Brewer HB Jr., Potter H: Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. Neurobiol Aging 1996, 17(5):773-780.

50. Miyata M, JD Smith: Apolipoprotein E allele-specific antioxidant activity effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996, 14(1):5-61.

51. Jordan J, Galindo MF, Miller RJ, Reardon CA, Getz GS, LaDu MJ: Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity within the pyramidal neuronal cultures. J Neurosci 1998, 18(1):195-204.

52. Herz J, Bock HH: Lipoprotein receptors in the nervous system. Annu Rev Biochem 2002, 71:405-434.

53. May P, Herz J, Bock HH: Molecular mechanisms of lipoprotein receptor signalling. Cell 2004, 117(2-3):225-238.

54. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK: Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. Embo J 1988, 7(13):4194-4127.

55. Raychowdhury R, Niles JL, McLuskey RT, Smith JA: Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Science 1989, 244(4909):1163-1165.

56. Takahashi S, Kawarabayashi Y, Nakai T, Sakai J, Yamamoto T: Rabbit very low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 1992, 89(19):9252-9256.

57. Kim DH, Iijima H, Goto K, Sakai J, Iishi H, Kim HJ, Suzuki H, Kondo H, Sae K, Yamamoto T: Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J Biol Chem 1996, 271(14):8373-8380.

58. Novak S, Hiesberger T, Schneider WJ, Nimipf J: A new low density lipoprotein receptor homologue with 8 ligand binding repeats in brain of chicken and mouse. J Biol Chem 1996, 271(20):11732-11736.

59. Brandes C, Novak S, Stockinger W, Herz J, Schneider WJ, Nimipf J: Avian and murine LRP88 and human apolipoprotein E receptor 2: Different presentation of products from corresponding genes. Genomics 1997, 42(2):185-191.

60. Jacobsen L, Madsen P, Moestrup SK, Lund AH, Tommerup N, Nykjaer A, Sottrup-Jensen L, Gliemann J, Petersen CM: Molecular characterization of a novel human hybrid-type receptor that binds to the LDL receptor. J Biol Chem 1993, 268 (39):31379-31383.

61. Yamazaki H, Bujo H, Kusunoki J, Seimiya K, Kanaki T, Morisaki N, Schmechel D, Saunders AM, Goldgaber D, Roses AC, Pericak-Vance M, Tanzi RE, Myers RR, Haines JL, Holmans P, Selkoe DJ, The Alzhiemer's Disease Collaborative Genetics Study: A dual role for apolipoprotein e in neurodegenerative disorders? Nat Genet 2000, 24(2):167(1):74-85.

62. Laskowitz DT, Thekdi AD, Thekdi SD, Han SK, Myers JK, Pizzo SV, Bennett ER: Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol 2001, 167(1):103-1035.

63. Lee JH, Tang Y, Wang H, Vitek MP, Bennett ER, Sullivan PM, Warner DS, Laskowitz DT: APOE genotype and an ApoE mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003, 278(49):48523-48532.

64. Guo L, LaDu MJ, Van Eldik LJ: A dual role for apolipoprotein E in neuroinflammation: anti- and pro-inflammatory activity. J Mol Neurosci 2004, 23(3):205-212.

65. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM: Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004, 10(7):719-726.

66. Trommer BL, Shah C, Yun SH, Gamkrelidze G, Pasternak ES, Stine WB, Manelli A, Sullivan P, Pasternak JF, LaDu MJ: ApoE isoform-specific effects on LTP: blockade by oligmeric amyloid-beta 1-42. Neurobiol Dis 2005, 18(1):75-82.
66. Liu CX, Musco S, Listinska NM, Forgacs E, Minna JD, Listyn NA: LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res 2000, 60(7):1961-1967.

67. Li Y, Cam J, Bu G: Low-density lipoprotein receptor family: endocytosis and signal transduction. Mol Neurobiol 2001, 23(1):53-67.

68. Leontович H, Meng W, Takagi J, Eck MJ, Springer TA, Blacklow SC: Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. Nat Struct Biol 2001, 8(6):499-504.

69. Bu G: Receptor-associated protein: a specialized chaperone and antagonist for members of the LDL receptor gene family. Curr Opin Lipidol 1998, 9(2):149-155.

70. Christie RH, Chung H, Rebeck GW, Strickland D, Hyman BT: Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system in Alzheimer’s disease. J Neuroapath Exp Neurol 1996, 55(4):491-498.

71. Clatworthy AE, Stockinger W, Christie RH, Schneider WJ, Nimipj J, Hyman BT, Rebeck GW: Expression and alternate splicing of apolipoprotein E receptor 2 in brain. Neuroscience 1999, 89(4-5):903-909.

72. Moestrup SK, Gliemann J, Fallesen G: Distribution of the alpha-2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res 1992, 269(3):375-382.

73. Sackton LW, Simmons DM, Hofmann SL, Goldstein JL, Brown MS: Localization of mRNA for low density lipoprotein receptor and a cholesterol synthetic enzyme in rabbit nervous system by in situ hybridization. Proc Natl Acad Sci U S A 1988, 85(24):9821-9825.

74. Li Y, Marzolo MP, van Kerkhof P, Strous GJ, Bu G: The YXXL motif, but not the two NFXPY motifs, serves as the dominant endocytosis signal for low density lipoprotein receptor-related protein. J Biol Chem 2000, 275(22):17187-17194.

75. Chen WJ, Goldstein JL, Brown MS: NFXPY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. J Biol Chem 1990, 265(6):3116-3123.

76. Li Y, Lu W, Marzolo MP, Bu G: Differential functions of members of the low-density lipoprotein receptor family suggested by their distinct endocytosis rates. J Biol Chem 2001, 276(21):18000-18006.

77. van Kerkhof P, Lee J, McCormick L, Tettault E, Lu W, Schoenfisch M, Oorschot V, Strous GJ, Klumperman J, Bu G: Sorting nexin 17 facilitates LRP4 recycling in the early endosome. Embo J 2005, 24(16):2851-2861.

78. Hoe HS, Magill LA, Guenette S, Bu G, Vicini S, Rebeck GW: FE65 interaction with the apoE receptor ApoER2. J Biol Chem 2006.

79. Dietschy JM, Turley SD: The reelin receptor ApoER2 recruits JNK-interacting proteins-1 and -2. J Biol Chem 2000, 275(33):25625-25632.

80. Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimipj J, Herz J: Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem 2000, 275(33):25616-25624.

81. Poirier J: Apolipoprotein E isotype-specific effects in neurodegenerative disorders. Cytoskeletal adaptope-protein E receptors and the amyloid precursor protein. J Biol Chem 1998, 273(50):33556-33560.

82. Howell BW, Lamier LM, Frank R, Gertler FB, Cooper JA: The disabled I phosphotyrosine-binding domain binds to the internalization signals of transmembrane glycoproteins and to phospholipids. Mol Cell Biol 1999, 19(7):5179-5188.

83. Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimipj J, Herz J: Apolipoprotein E mimetic peptides on N-methyl-D-aspartate excitotoxicity in primary rat neuronal-glial cell cultures. Neuroscience 2003, 114(5):437-445.

84. LaDu MJ, Shah JA, Reardon CA, Getz GS, Bu G, Hu J, Guo L, Van Eldik LJ: Apolipoprotein E signaling in primary neurons. Mol Neurobiol 2000, 18000-18006.

85. Christie RH, Chung H, Rebeck GW, Strickland D, Hyman BT: Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system in Alzheimer's disease. J Neuroapath Exp Neurol 1996, 55(4):491-498.

86. Hoe HS, Harris DC, Rebeck GW: Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem 2005, 91(1):144-155.
intramembrane proteolysis of the 600 kd low density lipoprotein receptor-related protein (LRP) occurs in a trans-Golgi compartment. Embry 1990, 9(6):1769-1776.

140. Quinn KA, Grimsley PG, Dey P, Tapner M, Chesterman CN, Owensby DA: Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J Biol Chem 1997, 272(33):20463-20466.

141. Grimsley PG, Quinn KA, Owensby DA: Soluble low-density lipoprotein receptor-related protein. Trends Cardiovasc Med 1998, 8(8):363-368.

142. Qiu Z, Strickland DK, Hyman BT, Rebeck GW: Elevation of LDL receptor-related protein levels via ligand interactions in Alzheimer disease and in vitro. J Neurochem Exp Neurol 2001, 60(5):430-440.

143. May P, Reddy YK, Herz J: Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated receptor trafficking. J Biol Chem 2002, 277(21):18733-18743.

144. Kinoshita A, Shah T, Tangredi MM, Strickland DK, Hyman BT: The intracellular domain of the low density lipoprotein receptor-related protein modulates transactivation mediated by amyloid precursor protein and Fe65. J Biol Chem 2003, 278(42):41182-41188.

145. Blumewiller CM, Qi H, Zagouras P, Artavanis-Tsakonas S: Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 1997, 90(2):281-291.

146. Logeat F, Bessis O, Brou C, Lebail O, Boulai S, Seidah NG, Israel A: The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proc Natl Acad Sci U S A 1998, 95(14):8108-8112.

147. Mumm JS, Schroeter EH, Saxena MT, Giesenier A, Tian X, Pan D, Ray WJ, Kopan R: A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell 2000, 5(2):197-206.

148. Hoe HS, Rebeck GW: Regulation of ApoE receptor proteolysis by ligand binding. Brain Res Mol Brain Res 2005, 137(1-2):31-39.

149. May P, Bock HH, Nimijy J, Herz J: Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase. J Biol Chem 2003, 278(39):37386-37392.

150. Iijima H, Miyazawa M, Sakai J, Magoori K, Ito MR, Suzuki H, Nose M, Kajiyama H: A single intracellular site mediates the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A 1999, 96(20):11041-11048.

151. Arend WP, Malyak M, Smith MF Jr., Wisheand TD, Slack JL, Simmons JE, Giri JG, Dower SK: Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994, 153(10):4766-4774.

152. Fernandez-Botran R, Chilton PM, Ms Y: Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy. Adv Immunol 1996, 63:269-336.

153. Mortier E, Bernard J, Piet A, Jacques Y: Natural, proteolytic release of a soluble form of human IL-15 receptor alpha chain that behaves as a potent, high affinity IL-15 antagonist. J Immunol 2004, 173(3):1681-1688.

154. Bierhaus A, Humpert PM, Morsch A, Wodtke T, Chavakis T, Arnold B, Stern DM, Nawroth PP: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005, 83(1):87-88.

155. Yang G, Ge H, Boucher A, Yu X, Li C: Modulation of direct leptin signaling by soluble leptin receptor. Mol Endocrinol 2004, 18(6):1354-1362.

156. Pasquale EB: Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005, 6(6):462-475.

157. Janes PW, Saha N, Barton WA, Kolev MW, Wimmer-Kleinamp SH, Nieviergall E, Brenchal CP, Hliman JP, Lackmann M, Nikolov DB: Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 2005, 123(2):291-304.

158. Hattori M, Osterfield M, Flanagan JG: Regulated cleavage of a contact-mediated axon repellent. Science 2000, 289(5483):1360-1363.

159. Marecky T, Scholte M, Ludwig A, Rose-John S, Brenchal CP, Hartmann D, Altevogt P, Saftig P, Reiss K: L1 is sequentially processed by two differentially activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol 2005, 25(20):9040-9053.

160. Slack BE, Siniaja MS, Blustrajnik JK: Collagen type I selectively activates ecdysdom domain shedding of the discoidin domain receptor I: Involvement of Src tyrosine kinase. J Cell Biochem 2006, 98(3):672-684.

161. Nandi D, Tailandi P, Kumar A, Chandu D: The ubiquitin-proteasome system. J Biosci 2006, 31(1):137-155.

162. Montourini N, Visconte V, Rossi G, Ragno P: Soluble and cleaved forms of the urokinase receptor: degradation products or active molecules? Thromb Haemost 2003, 90(2):192-198.

163. Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK, Bajari TM, Strasser V, Nimpf J, Schneider WJ, Stockinger W, Hiesberger T, Schneider WJ, Bajari TM, Strasser V, Nimpf J, Schneider WJ: Soluble LDL-R are regulated by immobilized LDL-R and LDL. J Biol Chem 1990, 265(3):22160-22169.

164. Bajari TM, Strasser V, Nimijy J, Schneider WJ: LDL receptor family: isolation, production, and ligand binding analysis. Methods 2005, 36(2):109-116.